A great case from Military Hospital using Boston Scientific WATCHMAN FLX, demonstrating reliable performance in LAA management.
The latest results of the Champion AF study showed: WATCHMAN FLX provided statistically superior protection from bleeding and similar efficacy compared to NOACs in patients with NVAF.
#WATCHMANFLX #structuralheart #AFib #cardiology #BostonScientific #DHSHungary #DeliveringHealthcareSolutions
The first Watchman FLX Pro implantation in Hungary has been successfully completed deploying the largest 40 mm device with outstanding performance.
The implantation achieved an excellent position with optimal sealing, reinforcing the role of LAAC as a powerful alternative care strategy for patients with non-valvular atrial fibrillation who require a non-pharmacological approach to thromboembolic risk…
We are proud to spotlight an LAAC procedure where Prof. Dr. Gábor DURAY and Team have achieved what they commendably call a “perfect implantation” of the Boston Scientific WATCHMAN FLX™ device!
The WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) procedure offers a one-time, minimally invasive alternative to lifelong anticoagulant therapy for patients with non-valvular atrial…
We were thrilled to celebrate the 100th Sentinel cerebral protection device use during TAVI procedure in Hungary, at University of Szeged with the Team of Dr. Zoltán Ruzsa! The Sentinel device from Boston Scientific is designed to capture and remove embolic debris during TAVI procedures, helping reduce the risk of periprocedural stroke. This important milestone…
An important step in protecting patients from stroke risk due to atrial fibrillation: we proudly celebrated the 300th Watchman FLX procedure in Hungary with the EP Team of Zala County Hospital.
Boston Scientific Watchman FLX is designed for left atrial appendage closure (LAAC), offering an alternative to long-term anticoagulation in selected patients with non-valvular AF.…
86-year-old female patient with paroxysmal atrial fibrillation and atrial flutter, a CHAD-VASC score of 7, and a HAS-BLED score of 4, presented with a high bleeding risk and a history of stroke. Given these factors, Left Atrial Appendage Closure (LAAC) was performed using the BostonScientific Watchman FLX device as an alternative to long-term anticoagulation therapy.…
We are thrilled to announce that DHS Hungary has been honored with the P4S (Partners for Success) Award, proudly earning the Gold Winner 2024 title!
This recognition highlights the relentless effort, commitment, and outstanding teamwork we've built with our fantastic partners across. Together we’ve made great progress in advancing cutting-edge solutions and enhancing patient care.…
Exciting news in the realm of stroke prevention! The OPTION Trial highlights the safety and effectiveness of left atrial appendage closure (LAAC) using the Watchman FLX™ device as an alternative to oral anticoagulants in patients undergoing AFib ablation.
This study reinforces the potential of LAAC to reduce stroke risk while addressing bleeding concerns, offering hope…
We recently performed a challenging TAVR using Boston Scientific ACURATE neo2 valve in a patient with:
Key Challenges:
Left coronary artery take-off at just 7.6 mm
Horizontal aorta
Severe femoral calcification
To ensure safe access, we utilized peripheral Shockwave technology, which helped modify the calcified femoral tract. Despite the complexities, ACURATE neo2’s three size options,…
The Acurate Neo2 delivery system's exceptional trackability enables solutions for even the most challenging cases.
Recently, a patient with severe aortic stenosis (AS) and significant calcification on the leaflets faced an additional challenge—a stubborn lesion in the abdominal tract. In a groundbreaking procedure at the University of Pécs, Dr. Gábor KASZA successfully deployed a Bentley…
The Left Atrial Appendage (LAA) closure is a crucial procedure to reduce the risk of thromboembolism in patients with non-valvular atrial fibrillation. Boston Scientific Watchman FLX device is particularly beneficial for patients who are at an increased risk for stroke and systemic embolism, as identified by CHA2DS2-VASc scores. It's especially valuable for those who are…
Boston Scientific Acurate neo2 keeps delivering excellent results! The PROVE registry studied a N=1044 patient population and features independent core lab analysis.
Want to learn more? Download the data sheet here: https://www.bostonscientific.com/content/dam/bostonscientific/StructuralHeart/tavi-resources/sh-1884402-aa-acurate-neo2-prove-data-1pager-v7.pdf
#DeliveringHealthcareSolutions #DHSHungary #TAVI #acurateneo2 #study #innovation #greatresults
